Encapsulated Rose Bengal Enhances the Photodynamic Treatment of Triple-Negative Breast Cancer Cells.

Rose Bengal lasers reactive oxygen species triple-negative breast cancer tumours

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
22 Jan 2024
Historique:
received: 04 12 2023
revised: 13 01 2024
accepted: 15 01 2024
medline: 26 1 2024
pubmed: 26 1 2024
entrez: 26 1 2024
Statut: epublish

Résumé

Among breast cancer subtypes, triple-negative breast cancer stands out as the most aggressive, with patients facing a 40% mortality rate within the initial five years. The limited treatment options and unfavourable prognosis for triple-negative patients necessitate the development of novel therapeutic strategies. Photodynamic therapy (PDT) is an alternative treatment that can effectively target triple-negative neoplastic cells such as MDA-MB-231. In this in vitro study, we conducted a comparative analysis of the PDT killing rate of unbound Rose Bengal (RB) in solution versus RB-encapsulated chitosan nanoparticles to determine the most effective approach for inducing cytotoxicity at low laser powers (90 mW, 50 mW, 25 mW and 10 mW) and RB concentrations (50 µg/mL, 25 µg/mL, 10 µg/mL and 5 µg/mL). Intracellular singlet oxygen production and cell uptake were also determined for both treatment modalities. Dark toxicity was also assessed for normal breast cells. Despite the low laser power and concentration of nanoparticles (10 mW and 5 µg/mL), MDA-MB-231 cells experienced a substantial reduction in viability (8 ± 1%) compared to those treated with RB solution (38 ± 10%). RB nanoparticles demonstrated higher singlet oxygen production and greater uptake by cancer cells than RB solutions. Moreover, RB nanoparticles display strong cytocompatibility with normal breast cells (MCF-10A). The low activation threshold may be a crucial advantage for specifically targeting malignant cells in deep tissues.

Identifiants

pubmed: 38276623
pii: molecules29020546
doi: 10.3390/molecules29020546
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Mir Muhammad Nasir Uddin (MMN)

School of Science, Western Sydney University, Penrith, NSW 2750, Australia.
Department of Pharmacy, Faculty of Biological Sciences, University of Chittagong, Chittagong 4331, Bangladesh.

Alina Bekmukhametova (A)

School of Science, Western Sydney University, Penrith, NSW 2750, Australia.

Anu Antony (A)

School of Science, Western Sydney University, Penrith, NSW 2750, Australia.

Shital K Barman (SK)

School of Science, Western Sydney University, Penrith, NSW 2750, Australia.

Jessica Houang (J)

School of Science, Western Sydney University, Penrith, NSW 2750, Australia.

Ming J Wu (MJ)

School of Science, Western Sydney University, Penrith, NSW 2750, Australia.

James M Hook (JM)

School of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.

Laurel George (L)

Advanced Materials Characterisation Facility, Western Sydney University, Penrith, NSW 2750, Australia.

Richard Wuhrer (R)

Advanced Materials Characterisation Facility, Western Sydney University, Penrith, NSW 2750, Australia.

Damia Mawad (D)

School of Materials Science and Engineering and Australian Centre for NanoMedicine, University of New South Wales, Kensington, NSW 2052, Australia.

Daniel Ta (D)

School of Science, Western Sydney University, Penrith, NSW 2750, Australia.

Herleen Ruprai (H)

School of Science, Western Sydney University, Penrith, NSW 2750, Australia.

Antonio Lauto (A)

School of Science, Western Sydney University, Penrith, NSW 2750, Australia.
Biomedical Engineering & Neuroscience Research Group, The MARCS Institute, Western Sydney University, Penrith, NSW 2750, Australia.

Classifications MeSH